Kesin Logo (Kesin Logo)
Levetiracetam Solution
Product Images NDC 81033-013
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 81033-013). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Kesin Pharma Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Levetiracetam Carton Label (Levetiracetam Carton Label 1)
Label for Levetiracetam Oral Solution USP 500 mg/5 mL by Kesin Pharma Corporation. The label indicates a 50-pack of 5 mL unit dose cups, marked Rx Only and for institutional use only. Storage instructions specify 68°F to 77°F (20°C to 25°C). Expiration and lot numbers are placeholders.*
Figure (Figure1)
A bar chart showing the percentage of patients across three groups: Placebo (7.4%), Levetiracetam 1,000 mg/day (37.1%), and Levetiracetam 3,000 mg/day (39.6%). The y-axis represents the percentage of patients, and the x-axis shows the treatment groups with sample sizes noted below each bar.*
Figure (Figure2)
A bar chart comparing the percentage of patients across three groups: placebo, levetiracetam 1,000 mg/day, and levetiracetam 2,000 mg/day. The y-axis represents the percentage of patients, showing values of 6.3% for placebo, 20.8% for levetiracetam 1,000 mg/day, and 35.2% for levetiracetam 2,000 mg/day. Sample sizes are noted below each group.*
Figure (Figure3)
A bar chart comparing the percentage of patients for placebo and levetiracetam 3,000 mg/day groups. The placebo group (N=140) shows 14.4% of patients, while the levetiracetam group (N=180) shows 39.4%. The y-axis represents the percentage of patients from 0% to 45%.*
Figure (Figure4)
A bar graph comparing the percentage of patients between Placebo (N=97) and Levetiracetam (N=101). The y-axis shows the percentage of patients from 0% to 45%. The Placebo group bar reaches approximately 19.6%, while the Levetiracetam group bar reaches approximately 44.6%, which is marked with an asterisk.*
Figure (Figure5)
A bar chart comparing the percentage of patients in two groups: Placebo (19.6%) and Levetiracetam (43.1%). The vertical axis represents the percentage of patients, highlighting a higher proportion in the Levetiracetam group. The sample sizes are 51 for Placebo and 58 for Levetiracetam.*
Figure (Figure6)
A bar chart comparing the percentage of patients responding to treatment with placebo versus levetiracetam. The left bar represents placebo with a response rate of 45.2%, and the right bar represents levetiracetam with a response rate of 72.2%. Patient counts are indicated as 84 for placebo and 79 for levetiracetam.*
Structure (Structure01)
Chemical structure of levetiracetam showing its molecular layout with labeled bonds and functional groups, including a pyrrolidone ring, an ethyl side chain, and an amide group.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
